Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) traded up 1.9% during mid-day trading on Friday . The stock traded as high as $374.90 and last traded at $372.06, with a volume of 626,998 shares changing hands. The stock had previously closed at $365.27.

Several equities research analysts recently issued reports on the stock. Robert W. Baird reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Saturday, April 2nd. Roth Capital reiterated a “buy” rating and set a $520.00 target price (down from $555.00) on shares of Regeneron Pharmaceuticals in a research report on Saturday, April 2nd. Piper Jaffray Cos. reiterated a “hold” rating and set a $443.00 target price on shares of Regeneron Pharmaceuticals in a research report on Saturday, April 2nd. Cowen and Company reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Sunday, April 17th. Finally, Leerink Swann reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Saturday, March 19th. One research analyst has rated the stock with a sell rating, fifteen have given a hold rating and fourteen have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $508.32.

The stock has a market cap of $38.98 billion and a PE ratio of 59.27. The stock has a 50 day moving average price of $370.34 and a 200 day moving average price of $400.58.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported $2.57 EPS for the quarter, missing analysts’ consensus estimates of $2.58 by $0.01. During the same period in the previous year, the business posted $2.88 EPS. The business earned $1.20 billion during the quarter, compared to the consensus estimate of $1.18 billion. The business’s revenue was up 38.0% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals Inc. will post $10.80 EPS for the current year.

In other news, major shareholder Sanofi acquired 64,731 shares of the company’s stock in a transaction dated Tuesday, June 14th. The stock was acquired at an average cost of $363.86 per share, with a total value of $23,553,021.66. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Arthur F. Ryan sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $396.64, for a total value of $396,640.00. Following the completion of the sale, the director now directly owns 40,500 shares of the company’s stock, valued at $16,063,920. The disclosure for this sale can be found here.

Several large investors have recently modified their holdings of REGN. Brown Advisory Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3.1% in the fourth quarter. Brown Advisory Inc. now owns 1,920 shares of the biopharmaceutical company’s stock worth $1,042,000 after buying an additional 58 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in shares of Regeneron Pharmaceuticals by 38.5% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 6,801 shares of the biopharmaceutical company’s stock worth $3,693,000 after buying an additional 1,889 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 4,557,687 shares of the biopharmaceutical company’s stock worth $2,474,232,000 after buying an additional 131,565 shares during the last quarter. GAM Holding AG boosted its stake in shares of Regeneron Pharmaceuticals by 3.9% in the fourth quarter. GAM Holding AG now owns 7,699 shares of the biopharmaceutical company’s stock worth $4,180,000 after buying an additional 291 shares during the last quarter. Finally, Mizuho Trust & Banking Co. Ltd. boosted its stake in shares of Regeneron Pharmaceuticals by 0.9% in the fourth quarter. Mizuho Trust & Banking Co. Ltd. now owns 114,567 shares of the biopharmaceutical company’s stock worth $62,804,000 after buying an additional 1,016 shares during the last quarter.

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.